0001237899-20-000014.txt : 20200310
0001237899-20-000014.hdr.sgml : 20200310
20200310160539
ACCESSION NUMBER: 0001237899-20-000014
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200309
FILED AS OF DATE: 20200310
DATE AS OF CHANGE: 20200310
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GOLDSTEIN JOSEPH L
CENTRAL INDEX KEY: 0001225474
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 20701557
MAIL ADDRESS:
STREET 1: DEPT OF PHARMACOLOGY K5 YUVER OF TEXAS
STREET 2: 5323 HARRY HINES BLVD
CITY: DALLAS
STATE: TX
ZIP: 75390
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2020-03-09
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001225474
GOLDSTEIN JOSEPH L
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
1
0
0
0
Common Stock
2020-03-09
4
M
0
2000
33.42
A
11643
D
Common Stock
2020-03-09
4
S
0
200
468.14
D
11443
D
Common Stock
2020-03-09
4
S
0
100
469.8
D
11343
D
Common Stock
2020-03-09
4
S
0
200
470.83
D
11143
D
Common Stock
2020-03-09
4
S
0
100
471.34
D
11043
D
Common Stock
2020-03-09
4
S
0
73
474.88
D
10970
D
Common Stock
2020-03-09
4
S
0
327
475.31
D
10643
D
Common Stock
2020-03-09
4
S
0
200
476.16
D
10443
D
Common Stock
2020-03-09
4
S
0
500
479.21
D
9943
D
Common Stock
2020-03-09
4
S
0
300
482.82
D
9643
D
Non-Qualified Stock Option (right to buy)
33.42
2020-03-09
4
M
0
2000
0.0
D
2021-01-03
Common Stock
2000
0
D
Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
Represents volume-weighted average price of sales of 327 shares of Company stock on March 9, 2020 at prices ranging from $475.19 to $475.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 9, 2020 at each separate price.
Represents volume-weighted average price of sales of 200 shares of Company stock on March 9, 2020 at prices ranging from $476.15 to $476.17. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 9, 2020 at each separate price.
Represents volume-weighted average price of sales of 500 shares of Company stock on March 9, 2020 at prices ranging from $479.05 to $479.34. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 9, 2020 at each separate price.
Represents volume-weighted average price of sales of 300 shares of Company stock on March 9, 2020 at prices ranging from $482.51 to $482.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 9, 2020 at each separate price.
The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
/s/**Joseph L. Goldstein
2020-03-09